A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant P. vivax dihydrofolate reductase-thymidylate synthase

Journal of Infectious Diseases

Volumn 196, Issue 3, 2007, Pages 467-474

  O'Neil, Michael T ^a,c   Korsinczky, Michael L J ^a,b   Gresty, Karryn J ^a   Auliff, Alyson ^a   Cheng, Qin ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; CLOCIGUANIL; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; PYRIMETHAMINE; THYMIDYLATE SYNTHASE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG RESISTANCE; IC 50; MALARIA; MOLECULAR MODEL; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIMALARIALS; BINDING SITES; DRUG RESISTANCE; GENE EXPRESSION REGULATION; MUTATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTEIN CONFORMATION; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 34447651337     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519286     Document Type: Article

References (38)

1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64:97-106.
2. Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM. Treatment of primaquine-resistant Plasmodium vivax malaria. Lancet 1992; 340:310.
3. Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixed-species malaria infections in humans. Trends Parasitol 2004; 20:233-40.
4. Mehlotra RK, Lorry K, Kastens W, et al. Random distribution of mixed species malaria infections in Papua New Guinea. Am J Trop Med Hyg 2000; 62:225-31.
5. Paul RE, Brockman A, Price RN, et al. Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand. Trans R Soc Trop Med Hyg 1999; 93:587-93.
6. Siripoon N, Snounou G, Yamogkul P, Na-Bangchang K, Thaithong S. Cryptic Plasmodium falciparum parasites in clinical P. vivax blood samples from Thailand. Trans R Soc Trop Med Hyg 2002; 96:70-1.
7. Snounou G, White NJ. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol 2004; 20: 333-9.
8. Zakeri S, Mamaghani S, Mehrizi AA, et al. Molecular evidence of mixed P. vivax and P. falciparum infections in northern Islamic Republic of Iran. East Mediterr Health J 2004; 10:336-42.
9. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963; 12:121-8.
10. Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 1979; 73:15-7.
11. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. Am J Trop Med Hyg 1982; 31:1-9.
12. Laing AB. Hospital and field trials of sulpormethoxine with pyrimethamine against Malaysian strains of Plasmodium falciparum and P. vivax. Med J Malaysia 1968; 23:15-19.
13. Martin DC, Arnold JD. Trimethoprim and sulfalene therapy of Plasmodium vivax. J Clin Pharmacol J New Drugs 1969; 9:155-9.
14. Rieckmann KH, Brewer GJ, Powell RD. Effects of diaphenylsulphone (dapsone) against Plasmodium vivax of South West Pacific origin. Trans R Soc Trop Med Hyg 1968; 62:649-53.
15. Hastings MD, Porter KM, Maguire JD, et al. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 2004; 189: 744-50.
16. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine- pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46:3947-53.
17. Fidock DA, Wellems TE. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 1997; 94:10931-6.
18. Hunt SY, Detering C, Varani G, et al. Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Mol Biochem Parasitol 2005; 144:198-205.
19. Imwong M, Pukrittakayamee S, Looareesuwan S, et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother 2001; 45:3122-7.
20. Kongsaeree P, Khongsuk P, Leartsakulpanich U, et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 2005; 102:13046-51.
21. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003; 10:357-65.
22. Eldin de Pecoulas P, Basco LK, Tahar R, Ouatas T, Mazabraud A. Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene 1998; 211:177-85.
23. Imwong M, Pukrittayakamee S, Renia L, et al. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 2003; 47:1514-21.
24. Bunyarataphan S, Leartsakulpanich U, Taweechai S, Tarnchompoo B, Kamchonwongpaisan S, Yuthavong Y. Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. Antimicrob Agents Chemother 2006; 50:3631-7.
25. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193:673-5.
26. Deitsch K, Driskill C, Wellems T. Transformation of malaria parasites by the spontaneous uptake and expression of DNA from human erythrocytes. Nucleic Acids Res 2001; 29:850-3.
27. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 1979; 16:710-8.
28. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87:3018-22.
29. Mookherjee S, Howard V, Nzila-Mouanda A, Watkins W, Sibley CH. Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. Am J Trop Med Hyg 1999; 61:131-40.
30. Canfield CJ, Milhous WK, Ager AL, et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993; 49:121-6.
31. Jensen NP, Ager AL, Bliss RA, et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 2001; 44:3925-31.
32. Sa JM, Yamamoto MM, Fernandez-Becerra C, et al. Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt, in Plasmodium falciparum and Dictyostelium discoideum. Mol Biochem Parasitol 2006; 150:219-28.
33. Zhang K, Rathod PK. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 2002; 296:545-7.
34. Leartsakulpanich U, Imwong M, Pukrittayakamee S, et al. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol 2002; 119:63-73.
35. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997; 94:1124-9.
36. Hastings MD, Sibley CH. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc Natl Acad Sci USA 2002; 99:13137-41.
37. Sano G, Morimatsu K, Horii T. Purification and characterization of dihydrofolate reductase of Plasmodium falciparum expressed by a synthetic gene in Escherichia coli. Mol Biochem Parasitol 1994; 63:265-73.
38. Sirawaraporn W, Yongkiettrakul S, Sirawaraporn R, Yuthavong Y, Santi DV. Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp Parasitol 1997; 87:245-52.